Volume 95 Issue 5 | p. 6 | News of The Week
Issue Date: January 30, 2017 | Web Date: January 26, 2017

Fighting buildup of tau protein in Alzheimer’s by targeting RNA

Antisense oligonucleotide therapy reduces tau in mice
Department: Science & Technology
News Channels: Biological SCENE
Keywords: neuroscience, Alzheimer’s, tau, antisense oligonucleotide, Spinraza, Ionis Pharmaceuticals

Efforts to treat Alzheimer’s disease by targeting the peptide amyloid-β have largely failed so far, but researchers are also pursuing another target: tau protein. Like amyloid-β, tau aggregates in the brains of Alzheimer’s patients.

Until now, strategies against tau have mainly involved the use of antibodies and small-molecule drugs. But Timothy M. Miller and colleagues at Washington University in St. Louis are taking a different approach. “We are turning down the production of the tau . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society